Literature DB >> 27609277

The role of AQP4 in neuromyelitis optica: More answers, more questions.

Xin Yang1, Bruce R Ransom2, Jian-Fang Ma3.   

Abstract

Neuromyelitis optica (NMO) is a recurrent inflammatory disease that preferentially targets the optic nerves and spinal cord. The presence of antibodies to the water channel protein aquaporin-4 (AQP4), expressed almost exclusively in astrocytes in the central nervous system (CNS), is a reliable biomarker for NMO. These antibodies, NMO-IgG, may be responsible for the sequential cascade of immune events, including IgG/IgM deposition, infiltration of granulocytes and complement-mediated cytotoxicity (i.e. astrocyte loss) and demyelination. This review summarizes current thinking about the role of NMO-IgG in the pathogenesis of this condition. New insights were also generated along with important additional questions.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Complement; Demyelination; Glutamate; Neuromyelitis optica; Potassium channel; Water channel protein aquaporin-4

Mesh:

Substances:

Year:  2016        PMID: 27609277     DOI: 10.1016/j.jneuroim.2016.06.002

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  10 in total

1.  Heterogeneity of Astrocytes in Grey and White Matter.

Authors:  Susanne Köhler; Ulrike Winkler; Johannes Hirrlinger
Journal:  Neurochem Res       Date:  2019-12-03       Impact factor: 3.996

Review 2.  Headache in Neuromyelitis Optica.

Authors:  Alina Masters-Israilov; Matthew S Robbins
Journal:  Curr Pain Headache Rep       Date:  2017-04

Review 3.  Neuromyelitis Optica: Deciphering a Complex Immune-Mediated Astrocytopathy.

Authors:  Jeffrey L Bennett; Gregory P Owens
Journal:  J Neuroophthalmol       Date:  2017-09       Impact factor: 3.042

4.  Emerging roles for dynamic aquaporin-4 subcellular relocalization in CNS water homeostasis.

Authors:  Mootaz M Salman; Philip Kitchen; Andrea Halsey; Marie Xun Wang; Susanna Törnroth-Horsefield; Alex C Conner; Jerome Badaut; Jeffrey J Iliff; Roslyn M Bill
Journal:  Brain       Date:  2022-03-29       Impact factor: 15.255

5.  Finding NMO.

Authors:  Richard Daneman
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2016-12-19

6.  A Rare Presentation of Neuromyelitis Optica Spectrum Disorders.

Authors:  Navneet K Singh; Alexander J Sweidan; Sarah Strube; Ignacio Carrillo-Nunez
Journal:  Clin Med Insights Case Rep       Date:  2018-02-05

7.  Safety and efficacy of mycophenolate mofetil in treating neuromyelitis optica spectrum disorders: a protocol for systematic review and meta-analysis.

Authors:  Mengyu Han; Luqi Nong; Ziqiang Liu; You Chen; Yang Chen; Huan Meng; Yali Qin; Zhijun Wang; Ming Jin
Journal:  BMJ Open       Date:  2020-11-30       Impact factor: 2.692

Review 8.  Complexity and wide range of neuromyelitis optica spectrum disorders: more than typical manifestations.

Authors:  Jinming Han; Meng-Ge Yang; Jie Zhu; Tao Jin
Journal:  Neuropsychiatr Dis Treat       Date:  2017-10-20       Impact factor: 2.570

9.  Safety and efficacy of plasma exchange for the treatment of optic neuritis in neuromyelitis optica spectrum disorders: A protocol for systematic review and meta-analysis.

Authors:  Mengyu Han; You Chen; Luqi Nong; Ziqiang Liu; Lu Hao; Zhijun Wang
Journal:  Medicine (Baltimore)       Date:  2020-07-10       Impact factor: 1.817

10.  C5a-Preactivated Neutrophils Are Critical for Autoimmune-Induced Astrocyte Dysregulation in Neuromyelitis Optica Spectrum Disorder.

Authors:  Paweł Piatek; Małgorzata Domowicz; Natalia Lewkowicz; Patrycja Przygodzka; Mariola Matysiak; Katarzyna Dzitko; Przemysław Lewkowicz
Journal:  Front Immunol       Date:  2018-07-23       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.